Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.
from Dementia Big http://ift.tt/1PSESTU
via Stopping Dementia
from WordPress http://ift.tt/1QmGlXW
via alcoholic dementia
http://ift.tt/1QmGmeF
No comments:
Post a Comment